NRAS (Proto-Oncogene GTPase): A Potent Drug Target and Biomarker for various cancers

Target Name: NRAS

NCBI ID: G4893

NRAS

NRAS (Proto-Oncogene GTPase): A Potent Drug Target and Biomarker for various cancers

Introduction

The rapid evolution of the G protein-coupled receptor (GPCR) family has led to the identification of numerous drug targets. GPCRs are a family of transmembrane proteins that play a crucial role in cellular signaling, particularly in the regulation of cell survival and growth. One of the most promising drug targets in the GPCR family is the neuroregulon-associated protein (NRAS), which has been shown to contribute to various diseases, including cancer. In this article, we will discuss the NRAS protein, its function, and its potential as a drug target and biomarker.

NRAS gene and function

The NRAS gene is located on chromosome 12q34 and encodes a 21-kDa protein. NRAS is a proto-oncogene GTPase, which means it has the ability to catalyze the transfer of a phosphate group from a GDP-bound protein to an RNA -bound protein (2).NRAS is a key regulator of the RAS/MAPK signaling pathway, which is involved in cell survival, growth, and transformation.

NRAS functions as a negative regulator of the RAS/MAPK pathway by inhibiting the activity of the protein kinase kinase (PKK) (4).PKK is a key enzyme in the RAS/MAPK pathway that activates the MAPK/ERK signaling pathway, which promotes cell survival and growth (5).NRAS achieves its function by binding to the PKK and inhibiting its activity, thereby inhibiting the signaling pathway that contributes to cancer cell growth and transformation.

NRAS as a drug target

NRAS has been identified as a potential drug target due to its involvement in various diseases, including cancer. Several studies have shown that inhibition of the NRAS pathway has anti-tumor effects in various models of cancer, including colon cancer, breast cancer, and melanoma.

NRAS has been shown to be overexpressed or mutated in various types of cancer, including colorectal cancer, gastric cancer, and skin cancer. In addition, NRAS has been associated with the development of resistance to chemotherapy in cancer patients. Therefore, targeting NRAS may be an effective strategy for cancer treatment.

NRAS as a biomarker

NRAS has also been used as a biomarker for various types of cancer. NRAS gene expression has been shown to be downregulated in various types of cancer, including colon cancer, breast cancer, and melanoma. In addition, NRAS has been shown to be associated with the outcomes of various cancer treatments, such as chemotherapy and radiation therapy. Therefore, measuring NRAS gene expression may be an effective way to monitor the effectiveness of cancer treatments and predict patient outcomes.

Conclusion

NRAS is a proto-oncogene GTPase that plays a crucial role in the regulation of cellular signaling. Its function as a negative regulator of the RAS/MAPK pathway has led to its identification as a potential drug target and biomarker for various types of cancer. In addition, NRAS has been shown to be involved in the development of cancer resistance, which may make it an effective strategy for cancer treatment. Further research is needed to fully understand the role of NRAS in cancer biology and to develop effective strategies for its targeting and use as a biomarker.

Protein Name: NRAS Proto-oncogene, GTPase

Functions: Ras proteins bind GDP/GTP and possess intrinsic GTPase activity

The "NRAS Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NRAS comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets